Strategic Acquisition Sherlock Biosciences was acquired by OraSure Technologies in 2024, signaling potential alignment with OraSure’s point-of-need and home diagnostics ecosystem. This suggests sales opportunities across broader diagnostic platforms, distribution channels, and integrated test workflows within OraSure’s customer base and partners.

Global Expansion Recent investments in a UK biomanufacturing facility and international footprint indicate capacity and interest in scaling diagnostics production. High potential for sales conversations around manufacturing services, supply chain capabilities, and international regulatory-ready test kits.

CRISPR Diagnostic Platform Sherlock is developing CRISPR-based diagnostics and even launched an AI-assisted operating system for CRISPR dx development. This points to opportunities in platform licensing, developer tooling, and collaboration with biotech firms seeking rapid, accurate molecular testing solutions.

Public Funding & Partnerships Past USDA SBIR funding and multiple government/academic collaborations suggest a favorable environment for grant-aligned projects. Potential sales angles include funded R&D partnerships, co-development programs, and institutional pilot collaborations.

Financial Scale & Demand Revenue range and substantial funding indicate a growing customer profile with appetite for scalable diagnostics. Targeted outreach to expand test offerings, integration with existing OraSure products, and enterprise-level service agreements could yield sizable deals.